Melanotan I (MT-1)

Last Updated: August 2026

Melanotan I (MT-1) is the research-market name for afamelanotide, a synthetic linear α-melanocyte-stimulating hormone (α-MSH) analog that is an approved prescription drug on both sides of the Atlantic: the FDA approved it as SCENESSE on October 8, 2019 (16 mg subcutaneous implant) to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP) and a history of phototoxic reactions,2 sources and the EU authorised it on 22 December 2014 for prevention of phototoxicity in adult EPP patients (under exceptional circumstances).1 source Gray-market "melanotan-1" vials sold by peptide vendors are not the approved SCENESSE implant — same molecule on the label, entirely different product, supply chain, and quality controls. It is also researched for photoprotective tanning effects and is sold as a research-use-only compound by third-party laboratories outside of the approved indication.

What is Melanotan I and how does the α-MSH-analog mechanism work?

Melanotan I (afamelanotide) is a synthetic 13-amino-acid linear α-MSH analog — [Nle4, D-Phe7]-α-MSH — in which norleucine replaces methionine at position 4 and D-phenylalanine replaces L-phenylalanine at position 7, changes that confer resistance to enzymatic degradation and a longer-acting, more potent profile than native α-MSH. It binds melanocortin receptors (MC1R primarily on melanocytes), stimulating eumelanin (the protective dark pigment) synthesis in skin. The mechanism produces protective pigmentation without UV exposure, the basis for the EPP indication and the cosmetic tanning interest. Evidence level: FDA- and EMA-approved (SCENESSE for EPP); Phase 3 evidence in EPP; cosmetic tanning research.

What does the clinical evidence show for Melanotan I?

Phase 3 trials in erythropoietic protoporphyria demonstrated significant increases in pain-free sun-exposure time, supporting EU authorisation of Scenesse in 2014 and FDA approval in 2019. In the two controlled trials described in the FDA approval announcement, implant recipients logged a median 64 hours of pain-free direct sunlight over 180 days versus 41 hours on placebo in one trial (n=93), and 6 hours over 270 days versus 0.75 hours in the second (n=74).1 source The compound is administered as a subcutaneous slow-release implant in approved EPP use. Cosmetic tanning research applications use injectable formulations off-label. Outside the EPP indication, afamelanotide is not approved for anything — cosmetic tanning use is unapproved everywhere (as of August 2026). Evidence level: Phase 3 (EPP; FDA- and EMA-approved); cosmetic tanning research not at regulatory-grade.

How does Melanotan I compare to Melanotan II?

Melanotan I is a linear α-MSH analog with selective MC1R binding; Melanotan II is a smaller cyclic analog with broader melanocortin receptor binding (MC1R + MC3R + MC4R + MC5R), producing different effects including significant sexual function and appetite effects in addition to pigmentation. The Melanotan 1 vs Melanotan 2 comparison covers receptors, effects, and regulatory status side by side.

What are the documented side effects of Melanotan I?

Side effects in Scenesse clinical use include injection-site reactions, mild fatigue, occasional headache, and the expected pigmentation effects. The FDA approval materials also list nausea, respiratory symptoms, and darkening of skin — including darkening of pre-existing moles, which is why twice-yearly full-body skin examinations are recommended during treatment.1 source Long-term safety has been characterized in the EMA-approved Scenesse use, with ongoing surveillance. The melanocortin receptor pathway raises theoretical concerns about melanoma risk (since melanocyte stimulation is involved), though clinical data has not surfaced increased melanoma incidence in approved use. Evidence level: Phase 3 safety; post-market surveillance under FDA and EMA approvals; long-term cosmetic-use safety less characterized.

What is the regulatory status of Melanotan I?

Afamelanotide is an approved prescription drug for one rare disease: the FDA approved SCENESSE (NDA 210797, 16 mg subcutaneous implant) on October 8, 2019, to increase pain-free light exposure in adult EPP patients with a history of phototoxic reactions,1 source and the EU authorised it on 22 December 2014 for prevention of phototoxicity in adult EPP patients — an authorisation granted under exceptional circumstances.1 source It is not approved for cosmetic tanning anywhere in the world. In Australia, melanotan products fall under prescription-only medicine controls (Schedule 4) and it is illegal to sell or advertise them as tanning agents.1 source Research-grade "melanotan-1" sold by third-party laboratories is a separate supply chain from the prescription implant and carries none of its pharmaceutical quality controls (as of August 2026). Regulatory context in are peptides legal regulatory status by country.

Why does Melanotan I vendor verification matter?

Because the EMA-approved Scenesse implant product is distinct from research-grade injectable Melanotan I sold by third-party laboratories — those are different supply chains with different quality controls. Research-grade material is subject to wider purity variance, and the structural distinction between Melanotan I and the smaller Melanotan II requires mass spectrometry verification. Compare vendors against the independent Melanotan I lab tests on file. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Melanotan I vendors?

Peptigrity collects independent third-party Certificates of Analysis for Melanotan I from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently Asked Questions

Is Melanotan I FDA-approved?

Yes — for one rare disease. The FDA approved afamelanotide as SCENESSE on October 8, 2019, a 16 mg implant to increase pain-free light exposure in adults with erythropoietic protoporphyria; the EU authorised it in December 2014. It is not approved for cosmetic tanning anywhere in the world, and gray-market "melanotan-1" vials are not the approved SCENESSE product.

Is Melanotan I legal to purchase?

The Scenesse implant is available by prescription in jurisdictions where Melanotan I is approved for EPP. Research-grade Melanotan I is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for cosmetic use. Australia is a hard exception: melanotans are Schedule 4 prescription-only medicines there, and selling or advertising them as tanning products is illegal — the TGA fined one supplier A$101,412 across 27 infringement notices in 2026.2 sources Country breakdown in peptide legal status guide.

How does Melanotan I differ from Melanotan II?

Melanotan I is a longer linear α-MSH analog with selective MC1R binding (primarily pigmentation effects); Melanotan II is a smaller cyclic analog with broader melanocortin receptor binding (pigmentation + sexual function + appetite effects). They produce substantially different effect profiles.

Does Melanotan I cause melanoma?

The melanocortin pathway is theoretically implicated in melanoma development, but EMA Scenesse post-market surveillance has not surfaced increased melanoma incidence in approved use. Long-term cosmetic-tanning use safety is less characterized than approved EPP use. Anyone considering Melanotan I use should consult a licensed physician about the underlying melanocortin biology.

How can I verify a Melanotan I vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. Mass spec distinguishes Melanotan I (longer linear) from Melanotan II (smaller cyclic). COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a Melanotan I dose?

No. The Scenesse EPP dose is administered as a slow-release implant under medical supervision. Cosmetic tanning use is not approved anywhere; protocols vary widely. Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. Afamelanotide is FDA- and EMA-approved as SCENESSE for erythropoietic protoporphyria only; research-grade melanotan-1 sold for laboratory use is not the approved product, and cosmetic tanning use is not approved anywhere. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.